

Reference

1. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S 2019 Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan. *Thyroid* **29**:1563-1571.
2. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A 2014 Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. *Thyroid* **24**:27-34.
3. Fukuoka O, Sugitani I, Ebina A, Toda K, Kawabata K, Yamada K 2016 Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance. *World J Surg* **40**:529-537.
4. Kwon H, Oh HS, Kim M, Park S, Jeon MJ, Kim WG, Kim WB, Shong YK, Song DE, Baek JH, Chung KW, Kim TY 2017 Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea. *J Clin Endocrinol Metab* **102**:1917-1925.
5. Brito JP, Ito Y, Miyauchi A, Tuttle RM 2016 A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. *Thyroid* **26**:144-149.
6. Moon JH, Kim JH, Lee EK, Lee KE, Kong SH, Kim YK, Jung WJ, Lee CY, Yoo RE, Hwangbo Y, Song YS, Kim MJ, Cho SW, Kim SJ, Jung EJ, Choi JY, Ryu CH, Lee YJ, Hah JH, Jung YS, Ryu J, Hwang Y, Park SK, Sung HK, Yi KH, Park DJ, Park YJ 2018 Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro). *Endocrinol Metab (Seoul)* **33**:278-286.
7. Sawka AM, Ghai S, Tomlinson G, Rotstein L, Gilbert R, Gullane P, Pasternak J, Brown D, de Almeida J, Irish J, Chepeha D, Higgins K, Monteiro E, Jones JM, Gafni A, Goldstein DP 2018 A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. *BMJ Open* **8**:e020298.
8. Sugitani I, Fujimoto Y, Yamada K 2014 Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. *World J Surg* **38**:673-678.
9. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma

- K, Miyauchi A 2004 Papillary microcarcinoma of the thyroid: how should it be treated? *World J Surg* **28**:1115-1121.
10. Sugitani I, Fujimoto Y 1999 Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. *Endocr J* **46**:209-216.
 11. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A 2003 An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* **13**:381-387.
 12. Choi JB, Lee WK, Lee SG, Ryu H, Lee CR, Kang SW, Jeong JJ, Nam KH, Lee EJ, Chung WY, Jo YS, Lee J 2018 Long-term oncologic outcomes of papillary thyroid microcarcinoma according to the presence of clinically apparent lymph node metastasis: a large retrospective analysis of 5,348 patients. *Cancer Manag Res* **10**:2883-2891.
 13. Reinke R, Mathiesen JS, Larsen SR, Hahn CH, Pedersen HB, Bentzen J, Schytte S, Godballe C, Londero SC, DATHYRCA AsfTDTTCG- 2019 Incidental and Non-incident Papillary Thyroid Microcarcinoma in Denmark 1996-2015: A national study on incidence, outcome and thoughts on active surveillance. *Cancer Epidemiol* **60**:46-50.
 14. 川野汐織 2019 成人の甲状腺微小乳頭癌経過観察開始時に全身検索は必要か? 第 52 回日本内分泌外科学会学術大会.
 15. Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y 2010 Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. *World J Surg* **34**:1222-1231.
 16. Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT 2017 Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. *JAMA Otolaryngol Head Neck Surg* **143**:1015-1020.
 17. Ito Y, Miyauchi A 2007 A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. *Nat Clin Pract Endocrinol Metab* **3**:240-248.
 18. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K, Miya A 2010 An observational trial for papillary thyroid microcarcinoma in Japanese patients. *World J Surg* **34**:28-35.
 19. Oh HS, Ha J, Kim HI, Kim TH, Kim WG, Lim DJ, Kim TY, Kim SW, Kim WB, Shong YK, Chung JH, Baek JH 2018 Active Surveillance of Low-Risk Papillary Thyroid

- Microcarcinoma: A Multi-Center Cohort Study in Korea. *Thyroid* **28**:1587-1594.
20. Oh HS, Kwon H, Song E, Jeon MJ, Kim TY, Lee JH, Kim WB, Shong YK, Chung KW, Baek JH, Kim WG 2019 Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma. *Thyroid* **29**:642-649.
 21. Miyauchi A, Ito Y 2019 Conservative Surveillance Management of Low-Risk Papillary Thyroid Microcarcinoma. *Endocrinol Metab Clin North Am* **48**:215-226.
 22. Miyauchi A, Ito Y, Oda H 2018 Insights into the Management of Papillary Microcarcinoma of the Thyroid. *Thyroid* **28**:23-31.
 23. Sugitani I 2018 Active surveillance for very low-risk papillary thyroid carcinoma: experience and perspectives from Japan. *Ann Thyroid* **3**:26-40.
 24. Ito Y, Miyauchi A, Oda H, Kobayashi K, Kihara M, Miya A 2016 Revisiting Low-Risk Thyroid Papillary Microcarcinomas Resected Without Observation: Was Immediate Surgery Necessary? *World J Surg* **40**:523-528.
 25. Rosario PWS, Mourao GF, Oliveira PHL, Silva TH 2018 Are Papillary Thyroid Carcinomas That Are Candidates for Active Surveillance in Fact Classical Microcarcinomas Restricted to the Gland? *Eur Thyroid J* **7**:258-261.
 26. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L 2016 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **26**:1-133.
 27. Jeon MJ, Chung MS, Kwon H, Kim M, Park S, Baek JH, Song DE, Sung TY, Hong SJ, Kim TY, Kim WB, Shong YK, Lee JH, Kim WG 2017 Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis. *Clin Endocrinol (Oxf)* **86**:845-851.
 28. Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H, Yamada K 2019 Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. *Thyroid* **29**:59-63.
 29. Miyauchi A, Kudo T, Ito Y, Oda H, Sasai H, Higashiyama T, Fukushima M, Masuoka H, Kihara M, Miya A 2018 Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. *Surgery* **163**:48-52.
 30. Miyauchi A, Kudo T, Ito Y, Oda H, Yamamoto M, Sasai H, Higashiyama T, Masuoka H, Fukushima M, Kihara M, Miya A 2019 Natural history of papillary thyroid microcarcinoma: Kinetic analyses on tumor volume during active surveillance and before presentation. *Surgery* **165**:25-30.

31. Ito Y, Miyauchi A, Kudo T, Higashiyama T, Masuoka H, Kihara M, Miya A 2019 Kinetic Analysis of Growth Activity in Enlarging Papillary Thyroid Microcarcinomas. *Thyroid* **29**:1765-1773.
32. 杉谷巖 蛭, 戸田和寿, 2019 無症候性微小乳頭癌の非手術経過観察において多発は進行の危険因子ではない 第 52 回 日本内分泌外科学会学術大会抄録集.
33. Roti E, degli Uberti EC, Bondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. *Eur J Endocrinol* **159**:659-673.
34. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH 2003 Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. *Cancer* **98**:31-40.
35. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Yamashita H, Shuto S 2002 Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. *World J Surg* **26**:897-902.
36. Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, Higashiyama T, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 Biological behavior and prognosis of familial papillary thyroid carcinoma. *Surgery* **145**:100-105.
37. Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, Bianco AR 1999 Familial papillary thyroid microcarcinoma: a new clinical entity. *Lancet* **353**:637-639.
38. Capezzone M, Secchi C, Fralassi N, Cantara S, Brillì L, Ciuoli C, Pilli T, Maino F, Forleo R, Pacini F, Castagna MG 2019 Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma? *J Endocrinol Invest* **42**:1205-1213.
39. Shindo H, Amino N, Ito Y, Kihara M, Kobayashi K, Miya A, Hirokawa M, Miyauchi A 2014 Papillary thyroid microcarcinoma might progress during pregnancy. *Thyroid* **24**:840-844.
40. Ito Y, Miyauchi A, Kudo T, Ota H, Yoshioka K, Oda H, Sasai H, Nakayama A, Yabuta T, Masuoka H, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A 2016 Effects of Pregnancy on Papillary Microcarcinomas of the Thyroid Re-Evaluated in the Entire Patient Series at Kuma Hospital. *Thyroid* **26**:156-160.
41. Hirokawa M, Kudo T, Ota H, Suzuki A, Miyauchi A 2016 Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance. *Endocr J* **63**:805-810.
42. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R 1998 Outcome of

- differentiated thyroid cancer in Graves' patients. *J Clin Endocrinol Metab* **83**:2805-2809.
43. Ozaki O, Ito K, Kobayashi K, Toshima K, Iwasaki H, Yashiro T 1990 Thyroid carcinoma in Graves' disease. *World J Surg* **14**:437-440; discussion 440-431.
 44. Hales IB, McElduff A, Crummer P, Clifton-Bligh P, Delbridge L, Hoschl R, Poole A, Reeve TS, Wilmshurst E, Wiseman J 1992 Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. *J Clin Endocrinol Metab* **75**:886-889.
 45. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H 2006 Prognosis of small thyroid cancer in patients with Graves' disease. *Br J Surg* **93**:434-439.
 46. Zhi J, Zhao J, Gao M, Pan Y, Wu J, Li Y, Li D, Yu Y, Zheng X 2018 Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases. *Int J Clin Oncol* **23**:59-65.
 47. Ghossein R, Ganly I, Biagini A, Robenshtok E, Rivera M, Tuttle RM 2014 Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. *Thyroid* **24**:245-253.
 48. Kuo EJ, Goffredo P, Sosa JA, Roman SA 2013 Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. *Thyroid* **23**:1305-1311.
 49. Tanaka A, Hirokawa M, Higuchi M, Suzuki A, Yamao N, Hayashi T, Kuma S, Miyauchi A 2019 Diagnostic clues indicating tall cell variants of papillary thyroid carcinoma in fine needle aspiration. *Diagn Cytopathol* **47**:452-457.
 50. Takagi N, Hirokawa M, Nobuoka Y, Higuchi M, Kuma S, Miyauchi A 2014 Diffuse sclerosing variant of papillary thyroid carcinoma: a study of fine needle aspiration cytology in 20 patients. *Cytopathology* **25**:199-204.
 51. Kim HI, Jang HW, Ahn HS, Ahn S, Park SY, Oh YL, Hahn SY, Shin JH, Kim JH, Kim JS, Chung JH, Kim TH, Kim SW 2018 High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance. *J Clin Endocrinol Metab* **103**:446-451.
 52. Sugitani I, Fujimoto Y 2011 Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. *Surgery* **150**:1250-1257.
 53. Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A 2018 Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. *World J Surg* **42**:615-622.
 54. Sanabria A 2018 Active Surveillance in Thyroid Microcarcinoma in a Latin-American Cohort. *JAMA Otolaryngol Head Neck Surg* **144**:947-948.

55. Oda H, Miyauchi A, Ito Y, Sasai H, Masuoka H, Yabuta T, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A 2017 Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. *Endocr J* **64**:59-64.
56. Lang BH, Wong CK 2015 A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. *Eur J Endocrinol* **173**:367-375.
57. Cibas ES, Ali SZ 2017 The 2017 Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* **27**:1341-1346.
58. Chen B, Zhang Z, Wang K, Shang M, Zhao S, Ding W, Du R, Yu Z, Xu X 2019 Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases. *Clin Hemorheol Microcirc* **73**:545-552.
59. Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J 2016 Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. *PLoS One* **11**:e0167414.
60. Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S 2015 BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. *Endocr Relat Cancer* **22**:159-168.
61. Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, Wang TS, Lubitz CC 2016 BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. *Thyroid* **26**:248-255.
62. Yu FX, Hu MX, Zhao HX, Niu LJ, Rong XY, Li WH, Zhu Q, Ying JM, Lyu N 2019 Precise Detection of Gene Mutations in Fine-Needle Aspiration Specimens of the Papillary Thyroid Microcarcinoma Using Next-Generation Sequencing. *Int J Endocrinol* **2019**:4723958.
63. Yabuta T, Matsuse M, Hirokawa M, Yamashita S, Mitsutake N, Miyauchi A 2017 TERT Promoter Mutations Were Not Found in Papillary Thyroid Microcarcinomas That Showed Disease Progression on Active Surveillance. *Thyroid* **27**:1206-1207.
64. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei G, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A 2015 TERT Promoter Mutations in Papillary Thyroid Microcarcinomas. *Thyroid* **25**:1013-1019.
65. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, Namba H,

- Ito M, Abrosimov A, Lushnikov E, Sekine I, Yamashita S 2005 Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. *Histopathology* **47**:248-256.
66. Oda H, Miyauchi A, Ito Y, Yoshioka K, Nakayama A, Sasai H, Masuoka H, Yabuta T, Fukushima M, Higashiyama T, Kihara M, Kobayashi K, Miya A 2016 Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. *Thyroid* **26**:150-155.
67. Hedman C, Djarv T, Strang P, Lundgren CI 2016 Determinants of long-term quality of life in patients with differentiated thyroid carcinoma - a population-based cohort study in Sweden. *Acta Oncol* **55**:365-369.
68. Sawka AM, Tsang RW, Brierley JD, Rotstein L, Segal P, Ezzat S, Goldstein DP 2016 Concerns of low-risk thyroid cancer survivors. *Acta Oncol* **55**:1252-1253.
69. Sawka AM, Brierley JD, Tsang RW, Rotstein L, Ezzat S, Goldstein DP 2016 Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. *Thyroid* **26**:474-475.
70. Sawka AM, Ezzat S, Goldstein DP 2016 Exploring the Life Impact of Treated Low-Risk Thyroid Cancer. *Endocr Pract* **22**:513-514.
71. Smulever A, Pitoia F 2019 Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America. *Arch Endocrinol Metab* **63**:462-469.
72. Davies L, Roman BR, Fukushima M, Ito Y, Miyauchi A 2019 Patient Experience of Thyroid Cancer Active Surveillance in Japan. *JAMA Otolaryngol Head Neck Surg* **145**:363-370.
73. Yoshida Y, Horiuchi K, Okamoto T 2020 Patients' view on the management of papillary thyroid microcarcinoma: active surveillance or surgery. *Thyroid*. ; doi: 10.1089/thy.2019.0420
74. Jeon MJ, Lee YM, Sung TY, Han M, Shin YW, Kim WG, Kim TY, Chung KW, Shong YK, Kim WB 2019 Quality of Life in Patients with Papillary Thyroid Microcarcinoma Managed by Active Surveillance or Lobectomy: A Cross-Sectional Study. *Thyroid* **29**:956-962.
75. Kong SH, Ryu J, Kim MJ, Cho SW, Song YS, Yi KH, Park DJ, Hwangbo Y, Lee YJ, Lee KE, Kim SJ, Jeong WJ, Chung EJ, Hah JH, Choi JY, Ryu CH, Jung YS, Moon JH, Lee EK, Park YJ 2019 Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro). *Thyroid* **29**:1089-1096.